ERBB2 and breast carcinoma: Overexpression of the human epidermal growth factor receptor 2 (HER2) is present in approximately 17% of breast cancer patients and has been associated with aggressive tumor behavior, decreased response to traditional therapies, and reduced survival [3,4].